SCHEMBL7234563

SCHEMBL7234563

CCCc1nc(N)c(C(N)=O)[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
RECQL P46063 1/20 0.39
GLA P06280 1/20 0.36
PDPK1 O15530 1/20 0.35
GDA Q9Y2T3 1/20 0.35
POLB P06746 2/20 0.34
BACE1 P56817 1/20 0.34
HSD17B10 Q99714 1/20 0.33
USP2 O75604 1/20 0.33
TSHR P16473 1/20 0.33
PI4KA P42356 1/20 0.33
PI4K2B Q8TCG2 1/20 0.33
PI4K2A Q9BTU6 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
IKBKB O14920 2/20 0.32
GPR84 Q9NQS5 5/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27609241 0.86 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDHTTRECQL
SCHEMBL5990880 0.82 MAPK1 (0.39) ALDH1A1KDM4EHPGDHTTRECQL
SCHEMBL30296121 0.82 POLB (0.38) ALDH1A1KDM4EGLAPDPK1POLB
SCHEMBL9199916 0.81 HPGD (0.46) ALDH1A1KDM4EHPGDHTTRECQL
SCHEMBL9137641 0.80 ALDH1A1 (0.65) ALDH1A1KDM4EHPGDHTTRECQL
SCHEMBL27344634 0.74 GLA (0.31) GLAPOLB
SCHEMBL2298861 0.72 PI4KA (0.41) ALDH1A1KDM4ERECQLGLAPOLB
SCHEMBL9283238 0.71 GABRP (0.38) KDM4EGLAPOLBUSP2TSHR
SCHEMBL11471657 0.71 GLA (0.36) ALDH1A1KDM4EGLAPOLBBACE1
SCHEMBL1079587 0.71 GLA (0.36) ALDH1A1KDM4EGLAPOLBBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073834-A1 Purine compounds having PDE IV inhibitory activity and methods of synthesis CAVALLA DAVID J (GB) 2003-04-17 US disclosed
US-20020028469-A1 Method of defining genus of chemical compound and method of designing molecules BURCH RONALD M (US) 2002-03-07 US disclosed
EP-1045850-A4 PURINE COMPOUNDS HAVING PDE IV INHIBITORY ACTIVITY AND METHODS OF SYNTHESIS EURO CELTIQUE SA (LU) 2001-10-31 EP disclosed
US-6211367-B1 REACTING AN 2-IMIDAZOLINE COMPOUND WITH A BENZALDEHYDE; REDUCTION EURO-CELTIQUE, S.A. (LU) 2001-04-03 US disclosed
CN-1281458-A Purine compounds having PDE IV inhibitory activity and methods of synthesis EURO CELTIQUE SA (LU) 2001-01-24 CN disclosed
EP-1045850-A1 PURINE COMPOUNDS HAVING PDE IV INHIBITORY ACTIVITY AND METHODS OF SYNTHESIS Euro-Celtique S.A. (LU) 2000-10-25 EP disclosed
WO-1999029694-A1 PURINE COMPOUNDS HAVING PDE IV INHIBITORY ACTIVITY AND METHODS OF SYNTHESIS EURO-CELTIQUE, S.A. (LU) 1999-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073834-A1 Purine compounds having PDE IV inhibitory activity and methods of synthesis PDE3B, PDE3A, PDE4A ALDH1A1 487/4885KDM4E 1278/4885HPGD 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.